나눔터
공지사항
의학정보
복지정책
환우회소식
회비 및 후원금 납부내역
헌팅턴병 메뉴얼
HOME > 나눔터 > 의학정보

작성자
huntington [작성일 : 2016-09-23 15:48:40 ]   
제목 Teva 제약회사에서 진행중인 임상시험 소식을 전해드립니다.

신경보호효과 개선을 위한 약(Pridopidine)으로 현재 2임상시험 중에 있으며 헌팅턴병 증상을 늦추는 효과를 보인다고 합니다.


아직은 임상시험 단계인 약이며 추가 임상시험 단계등의 결과나오면 소식전해드리겠습니다.





Trial finds Teva drug could slow Huntington's disease

 

http://www.globes.co.il/en/article-teva-pridopidine-could-slow-huntingtons-d

isease-1001153229

 

Globes Correspondent 09/19/2016

 

 

 

Teva Pharmaceutical Industries Ltd. <http://www.tevapharm.com/>  today

announced what could be a major breakthrough in the treatment of

Huntington's Disease (HD) with positive results from its exploratory Phase

II PRIDE-HD study. The trial found a statistically significant impact on the

endpoint of the progression of Huntington Disease at 52 weeks following

treatment with Pridopidine at certain doses versus placebo. The effect of

Pridopidine was further evident in a sub-population of patients with early

stage HD, an effect first observed at 26 weeks.

 

 

 

"Slowing down the progression of this disease has proven to be impossible

until now. These findings give us a reason to believe we may be finally

making progress in slowing deterioration of disease," said Spyros

Papapetropoulos, Teva's VP Clinical Development, Neurodegenerative Diseases.

 

 

 

 

This was a 52-week, dose-ranging trial of Pridopidine twice daily versus

placebo, in the treatment of Huntington disease (HD). The study was directed

at measuring improvement in motor function and the effect on HD progression.

An unusually high placebo effect, extending beyond that expected from

previous studies, limited the ability to determine treatment effects on

assessments of HD motor scores. Evidence of symptomatic impact, however, was

seen in the early stage HD patient sub-population, with improvement in Total

Motor Score (TMS) and dystonia observed at 26 and 52 weeks in this patient

sub-set (stage 1 HD) at specific doses.

 

 

 

The discovery of Pridopidine's previously unknown mode of action as a potent

agonist of the Sigma 1 Receptor (S1R) resulted in a change in PRIDE-HD study

design, from a 26-week study focused on symptoms, to a 52-week study focused

on exploring pridopidine's potential impact on disease progression, as

measured by Total Functional Capacity (TFC).

 

 

 

"I am encouraged by these results, which provide us with clear insights into

the approach to be taken in Phase III development", said Michael Hayden,

President of Teva Global R&D and Chief Scientific Officer. "My obvious hope

is that this will provide the HD community with a medicine capable of

slowing down the progression of this devastating disease."

 

 

 

"These study results are very important for the HD community and for the

continued development of pridopidine. Firstly, pridopidine's safety profile

has been confirmed and extended. Secondly, we now have a clearer idea of the

dosages to study in Phase 3. Lastly, we have some of the most encouraging

evidence to date about an intervention which may slow the inexorable

functional decline of HD," said Karl Kieburtz, M.D., M.P.H., Director of the

Clinical & Translational Science Institute at the University of Rochester

Medical Center.

 

 

 

The results seen in this exploratory study will need to be confirmed in a

Phase III program that will be developed in collaboration with relevant

regulatory agencies.

 

 

 

Pridopidine is an investigational, oral small molecule being developed for

the treatment of HD that exerts its effect as an agonist of S1R. S1R plays a

key role in neuroprotection through increased production of brain-derived

neurotrophic factor (BDNF). Levels of BDNF are decreased in HD and other

neurodegenerative disorders including Parkinson's disease, Alzheimer's

disease and ALS.

 

================================

 

 

 

Huntington Study Group PRIDE HD Study Information:

http://huntingtonstudygroup.org/current-clinical-trials/pride-hd-study/

 

.       No information available yet on enrolling for the Phase 3 study.

 

.       No facilities in Florida participated in the Phase II study:

https://clinicaltrials.gov/ct2/show/study/NCT02006472?show_locs=Y#locn

 

[ 새글 | 답글 | 수정 | 삭제 ] [ 목록 ]
[ 총게시물 : 120 | page : 6 ]
[ 정렬조건 : 등록일 | 조회  ]
순번 제목 조회 파일 등록일 작성자
120   유전 질환 재단(HDF) 컨퍼런스 2022 – 1일 차 735 22/08/26 운영자  
119   현재 임상 시험 중인 헌팅틴 저하 약물 AMT-130으로 치료받은 일부 사람... 857 22/08/10 운영자  
118   Novartis의 슬픈 소식: branaplam의 VIBRANT-HD 시험에서 투여 중단 682 22/07/24 운영자  
117   헌팅턴병에 대한 유전자 요법에 대한 uniQure의 업데이트 491 22/07/11 운영자  
116   인공 지능? 영리한 컴퓨터가 헌팅턴병을 이해하는 데 얼마나 도움이 됩 641 22/06/28 운영자  
115   헌팅턴병 진행을 추적하기 위한 새로운 로드맵 612 22/06/20 운영자  
114   HD에 대한 비타민 요법 622 22/06/15 운영자  
113   Huntington Study Group 컨퍼런스 발표내용 613 20/11/02 운영자  
112   HTT-C2 692 22/02/03 운영자  
111   고용량 비타민B 보충제 투약 임상실험 619 22/05/19 운영자  
110   헌팅턴병 치료 컨퍼런스 2022 - Day 3 743 22/06/03 운영자  
109   헌팅턴병 치료제 컨퍼런스 2022 - Day 2 658 22/05/27 운영자  
108   헌팅턴병 치료제 컨퍼런스 2022 - Day 1 656 22/05/15 운영자  
107   branaplam 한 숟가락은 헌팅틴 수치를 낮추는 데 도움이 됩니다. 787 22/03/02 운영자  
106   헌팅턴병에 대한 라퀴니모드의 LEGATO-HD 시험에서 나온 실망스러운 소 597 20/02/17 운영자  
105   로슈, '중추적인' 헌팅틴 저하 연구 세부사항 발표 594 20/03/21 운영자  
104   아이들도 때때로 헌팅턴병에 걸립니다 572 20/04/10 운영자  
103   헌팅턴병을 유발하는 단백질과의 전투에서 많은 전선에서 발전 561 20/05/25 운영자  
102   헌팅턴병을 예방하는 유전적 딸꾹질 621 20/05/06 운영자  
101   Roche의 Huntingtin 저하 시험을 위한 업데이트된 시험 디자인 589 20/06/24 운영자  

1 2 3 4 5 6 [ 새글 | 처음목록 | 목록 ]  
단체명 : 헌팅턴병 환우회   주소 : 서울시 종로구 연건동 서울대학교병원  

Copyrightⓒ by huntington.co.kr All rights reserved.    webmaster  개인정보 취급방침